BD Appoints Bridget Bagnato as President for Global Peripheral Intervention Division

Becton, Dickinson and Company (BD), a renowned global medical technology firm, has announced that Bridget Bagnato will assume the role of worldwide president for its Peripheral Intervention division, starting November 16, 2026. Based in Tempe, Arizona, Bagnato will be responsible for steering the global strategy, operations, and commercial performance of this vital business unit.

Peter Menziuso, the executive vice president and president of the Interventional segment at BD, expressed confidence in Bagnato's track record. He stated, "Bridget brings deep experience across BD and a strong understanding of our customers, with a proven ability to grow businesses through innovation and operational excellence." Menziuso is optimistic that Bagnato will further develop the technologies pertaining to peripheral vascular diseases, oncology, and end-stage kidney disease, which are crucial for addressing unmet medical needs and delivering substantial value to customers and patients alike.

Bagnato's career at BD spans over 27 years, during which she has held various leadership positions across multiple business units. Before her new appointment, she was the worldwide president of BD's Specimen Management unit. Her diverse experience also includes serving as vice president and general manager of Surgical Complication Solutions within the Medication Delivery Solutions and Surgery sectors.

A graduate of Villanova University, Bagnato holds a bachelor's degree and an MBA from The Fuqua School of Business at Duke University. Her extensive background equips her to tackle the challenges and opportunities within the Peripheral Intervention sector, which focuses on providing innovative solutions for patients undergoing treatment for chronic conditions.

BD is regarded as one of the leading pure-play medical technology companies, dedicated to advancing global health. The firm aims to enhance medical essentials, connected care, biopharma systems, and interventional technologies. With a global workforce of over 60,000 employees, BD is committed to delivering high-impact medical products and solutions. Their integrated approach aims to improve healthcare outcomes while lowering costs, enhancing clinical efficiencies, and increasing access to care.

The appointment of Bridget Bagnato as president is seen not only as a significant leadership move for BD but also a strategic step towards bolstering their commitment to innovative therapeutic approaches in the medical field. As she steps into her new role, stakeholders across the healthcare spectrum are keenly watching how her leadership will influence the evolution of Peripheral Intervention at BD.

For more information about BD and its advancements in medical technology, visit their official website or connect with them on social media platforms like LinkedIn and Instagram. The company's continued focus on collaborative partnerships with healthcare providers aims to enhance treatment outcomes for patients globally, thereby fulfilling its mission to advance the world of health.